GSK de­clares sec­ond PhI­II win for Blenrep com­bo in bid to re­vive drug

Blenrep, GSK’s BC­MA-tar­get­ing an­ti­body-drug con­ju­gate, has once again beat the stan­dard of care when giv­en as part of a com­bi­na­tion to pa­tients with re­lapsed/re­frac­to­ry mul­ti­ple myelo­ma who have re­ceived at least one treat­ment, the British drug­mak­er said.

GSK has been build­ing its case for bring­ing the can­cer drug back to mar­ket af­ter yank­ing it from the US in 2022 on dis­ap­point­ing con­fir­ma­to­ry da­ta. Blenrep had been grant­ed an ac­cel­er­at­ed ap­proval in 2020 as a monother­a­py but failed to im­prove pro­gres­sion-free sur­vival (PFS) over the PomDex reg­i­men, which com­pris­es po­ma­lido­mide and low-dose dex­am­etha­sone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER